- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Daily Derm Times: July 8, 2025
Author(s):
Key Takeaways
- Briquilimab trials demonstrate strong efficacy and safety for chronic spontaneous urticaria, overcoming manufacturing challenges.
- AI model improves early detection of high-risk cutaneous squamous cell carcinoma through advanced histopathological assessments.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Jasper Investigates Drug Lot Issue in CSU Study
Jasper Therapeutics reveals promising results from briquilimab trials for chronic spontaneous urticaria, showcasing strong efficacy and safety despite manufacturing challenges.
New AI Model Aids Early CSCC Risk Stratification
AI enhances early detection of high-risk cutaneous squamous cell carcinoma (CSCC) by integrating advanced histopathological assessments for improved patient outcomes.
ILDS, ISD Commemorate World Skin Health Day 2025 With ‘No Health without Skin Health’ Theme
World Skin Health Day 2025 unites global leaders to advocate for skin health equity, emphasizing the urgent need for accessible dermatological care worldwide.
Data Shows Spesolimab Maintains Skin Clarity Between GPP Flares
Spesolimab effectively targets IL-36 receptor, reducing inflammation and preventing flares in generalized pustular psoriasis, offering new hope for patients.
Q&A With the NEA: Vetting Eczema-Safe Products Through the Seal of Acceptance
The NEA’s Sam Iannotti, MPH, discusses how the Seal of Acceptance helps patients and clinicians identify products that meet rigorous eczema care standards.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
